Magnetic resonance imaging and positron emission tomography approaches to imaging vascular and cardiac inflammation

Circulation Journal

Volumn 80, Issue 6, 2016, Pages 1269-1277

  Amsallem, Myriam ^a   Saito, Toshinobu ^a   Tada, Yuko ^a   Dash, Rajesh ^a   McConnell, Michael V ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Inflammation; Magnetic resonance; Noninvasive imaging; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROTEINASE;

ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOGENESIS; APOPTOSIS; BLOOD VESSEL PERMEABILITY; CARDIAC GRAFT REJECTION; CARDIOVASCULAR RISK; CARDITIS; EDEMA; FIBROSIS; FLUORINE NUCLEAR MAGNETIC RESONANCE; HUMAN; HYPERMETABOLISM; MYOCARDITIS; NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SARCOIDOSIS; VASCULITIS; BLOOD VESSEL; CARDIOVASCULAR DISEASE; DIAGNOSTIC IMAGING; INFLAMMATION; PATHOLOGY;

BLOOD VESSELS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MYOCARDITIS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84969631077     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-16-0224     Document Type: Review

References (84)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 2015; 131: 29-322.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
4. De Paoli F, Staels B, Chinetti-Gbaguide G. Macrophage phenotypes and their modulation in atherosclerosis. Circ J 2014; 78: 1775-1781.
5. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: Angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054-2061.
6. Dale MA, Ruhlman MK, Baxter BT. Inflammatory cell phenotypes in AAAs: Their role and potential as targets for therapy. Arterioscler Thromb Vasc Biol 2015; 35: 1746-1755.
7. Hellenthal FAMVI, Buurman WA, Wodzig WKWH, Schurink GWH. Biomarkers of abdominal aortic aneurysm progression. Part 2: Inflammation. Nat Rev Cardiol 2009; 6: 543-552.
8. Tedesco MM, Terashima M, Blankenberg FG, Levashova Z, Spin JM, Backer MV, et al. Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol 2009; 29: 1452-1457.
9. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-1084.
10. Simonetti OP, Finn JP, White RD, Laub G, Henry DA. "Black blood" T2-weighted inversion-recovery MR imaging of the heart. Radiology 1996; 199: 49-57.
11. Miller DD, Holmvang G, Gill JB, Dragotakes D, Kantor HL, Okada RD, et al. MRI detection of myocardial perfusion changes by gadolinium- DTPA infusion during dipyridamole hyperemia. Magn Reson Med 1989; 10: 246-255.
12. Luetkens JA, Doerner J, Thomas DK, Dabir D, Gieseke J, Sprinkart AM, et al. Acute myocarditis: Multiparametric cardiac MR imaging. Radiology 2014; 273: 383-392.
13. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. Am J Roentgenol 2008; 190: 151-156.
14. Cheng VY, Slomka PJ, Ahlen M, Thomson LEJ, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial. J Nucl Cardiol 2010; 17: 286-291.
15. Miyagawa M, Yokoyama R, Nishiyama Y, Ogimoto A, Higaki J, Mochizuki T. Positron emission tomography-computed tomography for imaging of inflammatory cardiovascular diseases. Circ J 2014; 78: 1302-1310.
16. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Eur Radiol 2001; 11: 2319-2331.
17. Terashima M, Uchida M, Kosuge H, Tsao PS, Young MJ, Conolly SM, et al. Human ferritin cages for imaging vascular macrophages. Biomaterials 2011; 32: 1430-1437.
18. Kosuge H, Sherlock SP, Kitagawa T, Terashima M, Barral JK, Nishimura DG, et al. FeCo/graphite nanocrystals for multi-modality imaging of experimental vascular inflammation. PloS One 2011; 6: e14523, doi:10.1371/journal.pone.0014523.
19. Ahrens ET, Zhong J. In vivo MRI cell tracking using perfluorocarbon probes and fluorine-19 detection. NMR Biomed 2013; 26: 860-871.
20. Flögel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 2008; 118: 140-148.
21. Temme S, Jacoby C, Ding Z, Bönner F, Borg N, Schrader J, et al. Technical advance: Monitoring the trafficking of neutrophil granulocytes and monocytes during the course of tissue inflammation by noninvasive 19F MRI. J Leukoc Biol 2014; 95: 689-697.
22. Lam J, Simpson PC, Yang PC, Dash R. Synthesis of an in vivo MRIdetectable apoptosis probe. J Vis Exp 2012; (65): 3775, doi:10. 3791/3775.
23. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: Angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054-2061.
24. Gaens ME, Backes WH, Rozel S, Lipperts M, Sanders SN, Jaspers K, et al. Dynamic contrast-enhanced MR imaging of carotid atherosclerotic plaque: Model selection, reproducibility, and validation. Radiology 2013; 266: 271-279.
25. Ishida A, Murray J, Saito Y, Kanthou C, Benzakour O, Shibuya M, et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 2001; 188: 359-368.
26. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001; 97: 785-791.
27. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res 1995; 77: 1129-1135.
28. Antonov AS, Kolodgie FD, Munn DH, Gerrity RG. Regulation of macrophage foam cell formation by alphaVbeta3 integrin: Potential role in human atherosclerosis. Am J Pathol 2004; 165: 247-258.
29. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, et al. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: A PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology 2011; 260: 182-191.
30. Amirbekian V, Aguinaldo JGS, Amirbekian S, Hyafil F, Vucic E, Sirol M, et al. Atherosclerosis and matrix metalloproteinases: Experimental molecular MR imaging in vivo. Radiology 2009; 251: 429-438.
31. Jellis CL, Kwon DH. Myocardial T1 mapping: Modalities and clinical applications. Cardiovasc Diagn Ther 2014; 4: 126-137.
32. Barral JK, Gudmundson E, Stikov N, Etezadi-Amoli M, Stoica P, Nishimura DG. A robust methodology for in vivo T1 mapping. Magn Reson Med 2010; 64: 1057-1067.
33. Kellman P, Wilson JR, Xue H, Bandettini WP, Shanbhag SM, Druey KM, et al. Extracellular volume fraction mapping in the myocardium, part 2: Initial clinical experience. J Cardiovasc Magn Reson 2012; 14: 64.
34. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007; 116: 2841-2850.
35. Vengrenyuk Y, Carlier S, Xanthos S, Cardoso L, Ganatos P, Virmani R, et al. A hypothesis for vulnerable plaque rupture due to stressinduced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci USA 2006; 103: 14678-14683.
36. Dweck MR, Chow MWL, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18F-sodium fluoride uptake: A novel marker of plaque biology. J Am Coll Cardiol 2012; 59: 1539-1548.
37. Kerwin WS, O'Brien KD, Ferguson MS, Polissar N, Hatsukami TS, Yuan C. Inflammation in carotid atherosclerotic plaque: A dynamic contrast-enhanced MR imaging study. Radiology 2006; 241: 459-468.
38. Kerwin W, Hooker A, Spilker M, Vicini P, Ferguson M, Hatsukami T, et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 2003; 107: 851-856.
39. Gury-Paquet L, Millon A, Salami F, Cernicanu A, Scoazec JY, Douek P, et al. Carotid plaque high-resolution MRI at 3 T: Evaluation of a new imaging score for symptomatic plaque assessment. Magn Reson Imaging 2012; 30: 1424-1431.
40. Tang TY, Howarth SPS, Miller SR, Graves MJ, Patterson AJ, U-King-Im JM, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study: Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009; 53: 2039-2050.
41. Alam SR, Stirrat C, Richards J, Mirsadraee S, Semple SIK, Tse G, et al. Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide. J Cardiovasc Magn Reson 2015; 17: 83.
42. Saam T, Rominger A, Wolpers S, Nikolaou K, Rist C, Greif M, et al. Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: A PET/CT study. Eur J Nucl Med Mol Imaging 2010; 37: 1203-1212.
43. Rudd JHF, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: A prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009; 2: 107-115.
44. Wu YW, Kao HL, Chen MF, Lee BC, Tseng WYI, Jeng JS, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med 2007; 48: 227-233.
45. Choi HY, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, et al. Association of adiponectin, resistin, and vascular inflammation: Analysis with 18F-fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol 2011; 31: 944-949.
46. Yoo HJ, Kim S, Park MS, Yang SJ, Kim TN, Seo JA, et al. Vascular inflammation stratified by C-reactive protein and low-density lipoprotein cholesterol levels: Analysis with 18F-FDG PET. J Nucl Med 2011; 52: 10-17.
47. Wu YW, Kao HL, Huang CL, Chen MF, Lin LY, Wang YC, et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging 2012; 39: 399-407.
48. Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011; 4: 1110-1118.
49. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003; 108: 2270-2274.
50. Kitagawa T, Kosuge H, Chang E, James ML, Yamamoto T, Shen B, et al. Integrin-targeted molecular imaging of experimental abdominal aortic aneurysms by (18)F-labeled Arg-Gly-Asp positron-emission tomography. Circ Cardiovasc Imaging 2013; 6: 950-956.
51. Joshi NV, Vesey AT, Williams MC, Shah ASV, Calvert PA, Craighead FHM, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. Lancet 2014; 383: 705-713.
52. Bazeli R, Coutard M, Duport BD, Lancelot E, Corot C, Laissy JP, et al. In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol 2010; 45: 662-668.
53. Richards JMJ, Semple SI, MacGillivray TJ, Gray C, Langrish JP, Williams M, et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: A pilot study. Circ Cardiovasc Imaging 2011; 4: 274-281.
54. Sakalihasan N, Van Damme H, Gomez P, Rigo P, Lapiere CM, Nusgens B, et al. Positron emission tomography (PET) evaluation of abdominal aortic aneurysm (AAA). Eur J Vasc Endovasc Surg 2002; 23: 431-436.
55. Reeps C, Essler M, Pelisek J, Seidl S, Eckstein HH, Krause BJ. Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J Vasc Surg 2008; 48: 417-423.
56. Truijers M, Kurvers HAJM, Bredie SJH, Oyen WJG, Blankensteijn JD. In vivo imaging of abdominal aortic aneurysms: Increased FDG uptake suggests inflammation in the aneurysm wall. J Endovasc Ther 2008; 15: 462-467.
57. Xu XY, Borghi A, Nchimi A, Leung J, Gomez P, Cheng Z, et al. High levels of 18F-FDG uptake in aortic aneurysm wall are associated with high wall stress. Eur J Vasc Endovasc Surg 2010; 39: 295-301.
58. Courtois A, Nusgens BV, Hustinx R, Namur G, Gomez P, Somja J, et al. 18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nucl Med 2013; 54: 1740-1747.
59. Yoshihara T, Shimada K, Fukao K, Sai E, Sato-Okabayashi Y, Matsumori R, et al. Omega 3 polyunsaturated fatty acids suppress the development of aortic aneurysms through the inhibition of macrophage- mediated inflammation. Circ J 2015; 79: 1470-1478.
60. Shinagawa H, Frantz S. Cellular immunity and cardiac remodeling after myocardial infarction: Role of neutrophils, monocytes, and macrophages. Curr Heart Fail Rep 2015; 12: 247-254.
61. Ferreira VM, Piechnik SK, Dall'Armellina E, Karamitsos TD, Francis JM, Ntusi N, et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: Comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging 2013; 6: 1048-1058.
62. Dall'Armellina E, Piechnik SK, Ferreira VM, Si QL, Robson MD, Francis JM, et al. Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovasc Magn Reson 2012; 14: 15.
63. Alam SR, Shah ASV, Richards J, Lang NN, Barnes G, Joshi N, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: Early clinical experience. Circ Cardiovasc Imaging 2012; 5: 559-565.
64. Bönner F, Merx MW, Klingel K, Begovatz P, Flögel U, Sager M, et al. Monocyte imaging after myocardial infarction with 19F MRI at 3 T: A pilot study in explanted porcine hearts. Eur Heart J Cardiovasc Imaging 2015; 16: 612-620.
65. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology: Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007; 50: 1914-1931.
66. Borchert B, Lawrenz T, Bartelsmeier M, Röthemeyer S, Kuhn H, Stellbrink C. Utility of endomyocardial biopsy guided by delayed enhancement areas on magnetic resonance imaging in the diagnosis of cardiac sarcoidosis. Clin Res Cardiol 2007; 96: 759-762.
67. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009; 53: 1475-1487.
68. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of biopsy-proven viral myocarditis: Predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012; 59: 1604-1615.
69. De Cobelli F, Pieroni M, Esposito A, Chimenti C, Belloni E, Mellone R, et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol 2006; 47: 1649-1654.
70. Radunski UK, Lund GK, Stehning C, Schnackenburg B, Bohnen S, Adam G, et al. CMR in patients with severe myocarditis: Diagnostic value of quantitative tissue markers including extracellular volume imaging. JACC Cardiovasc Imaging 2014; 7: 667-675.
71. Moon H, Park HE, Kang J, Lee H, Cheong C, Lim YT, et al. Noninvasive assessment of myocardial inflammation by cardiovascular magnetic resonance in a rat model of experimental autoimmune myocarditis. Circulation 2012; 125: 2603-2612.
72. Ishida Y, Yoshinaga K, Miyagawa M, Moroi M, Kondoh C, Kiso K, et al. Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med 2014; 28: 393-403.
73. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53: 241-248.
74. Momose M, Fukushia K, Kondo C, Serizawa N, Suzuki A, Abe K, et al. Diagnosis and detection of myocardial injury in active cardiac sarcoidosis: Significance of myocardial fatty acid metabolism and myocardial perfusion mismatch. Circ J 2015; 79: 2669-2676.
75. Manabe O, Ohira H, Yoshinaga K, Sato T, Klaipetch A, Oyama- Manabe N, et al. Elevated (18)F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis. Eur J Nucl Med Mol Imaging 2013; 40: 1558-1566.
76. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63: 329-336.
77. Wu YL, Ye Q, Foley LM, Hitchens TK, Sato K, Williams JB, et al. In situ labeling of immune cells with iron oxide particles: An approach to detect organ rejection by cellular MRI. Proc Natl Acad Sci USA 2006; 103: 1852-1857.
78. Flögel U, Su S, Kreideweiss I, Ding Z, Galbarz L, Fu J, et al. Noninvasive detection of graft rejection by in vivo (19)F MRI in the early stage. Am J Transplant 2011; 11: 235-244.
79. Hyafil F, Schindler A, Sepp D, Obenhuber T, Bayer-Karpinska A, Boeckh-Behrens T, et al. High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined (18)F-FDG PET/MR imaging. Eur J Nucl Med Mol Imaging 2016; 43: 270-279.
80. Calcagno C, Ramachandran S, Izquierdo-Garcia D, Mani V, Millon A, Rosenbaum D, et al. The complementary roles of dynamic contrast- enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. Eur J Nucl Med Mol Imaging 2013; 40: 1884-1893.
81. Wu HH, Gurney PT, Hu BS, Nishimura DG, McConnell MV. Freebreathing multiphase whole-heart coronary MR angiography using image-based navigators and three-dimensional cones imaging. Magn Reson Med 2013; 69: 1083-1093.
82. Ratib O, Nkoulou R. Potential applications of PET/MR imaging in cardiology. J Nucl Med 2014; 55: 40-46.
83. 18F-fluorodeoxyglucose PET/MRI in cardiac sarcoidosis. J Nucl Cardiol 2015 December 1, doi:10.1007/s12350-015-0348-4.
84. Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, et al. Feasibility of FDG imaging of the coronary arteries: Comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging 2010; 3: 388-397.